Mad2L1 Antibody [L3N17] | Primary Antibodies

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000

Application
WB, IHC

Reactivity
Human

Source
Mouse Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
24 kDa 24 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
Mad2L1 Antibody [L3N17] detects endogenous levels of total Mad2L1 protein.

Clone
L3N17

Synonym(s)
MAD2, MAD2L1, Mitotic spindle assembly checkpoint protein MAD2A, HsMAD2, Mitotic arrest deficient 2-like protein 1, MAD2-like protein 1

Background
Mad2L1, a pivotal component of the spindle assembly checkpoint (SAC) within the MAD/BUB protein family, safeguards genomic integrity by delaying anaphase onset until bi-orientation of all kinetochores on the mitotic spindle. The protein adopts open (O-Mad2) and closed (C-Mad2) conformations, with C-Mad2 forming a stable tetramer with Mad1 at unattached kinetochores to catalyze O-Mad2 conversion and template Cdc20 binding, generating the mitotic checkpoint complex (MCC) comprising Mad2, BubR1, Bub3, and Cdc20. MCC binding to APC/C inhibits its E3 ubiquitin ligase activity, stabilizing securin and cyclin B1 to prevent separase activation and sister chromatid separation; microtubule attachment and tension relieve SAC via Aurora B-mediated stripping of Knl1 and PP1 recruitment, disassembling MCC and licensing anaphase. Mad2 overexpression destabilizes microtubule plus ends through EB1 interaction, promoting microtubule catastrophe and merotelic attachments independent of checkpoint signaling, while nuclear Mad2 binds E2F1 to repress transcription. Ubiquitously expressed but elevated in proliferative tissues, Mad2L1 ensures faithful chromosome segregation critical for development and tissue renewal. Dysregulation drives chromosomal instability (CIN) hallmarking cancers, where overexpression correlates with aneuploidy, proliferation, poor prognosis, and chemoresistance in oral, gastric, and other carcinomas; silencing induces senescence, underscoring therapeutic potential via SAC modulation.

Background

Mad2L1, a pivotal component of the spindle assembly checkpoint (SAC) within the MAD/BUB protein family, safeguards genomic integrity by delaying anaphase onset until bi-orientation of all kinetochores on the mitotic spindle. The protein adopts open (O-Mad2) and closed (C-Mad2) conformations, with C-Mad2 forming a stable tetramer with Mad1 at unattached kinetochores to catalyze O-Mad2 conversion and template Cdc20 binding, generating the mitotic checkpoint complex (MCC) comprising Mad2, BubR1, Bub3, and Cdc20. MCC binding to APC/C inhibits its E3 ubiquitin ligase activity, stabilizing securin and cyclin B1 to prevent separase activation and sister chromatid separation; microtubule attachment and tension relieve SAC via Aurora B-mediated stripping of Knl1 and PP1 recruitment, disassembling MCC and licensing anaphase. Mad2 overexpression destabilizes microtubule plus ends through EB1 interaction, promoting microtubule catastrophe and merotelic attachments independent of checkpoint signaling, while nuclear Mad2 binds E2F1 to repress transcription. Ubiquitously expressed but elevated in proliferative tissues, Mad2L1 ensures faithful chromosome segregation critical for development and tissue renewal. Dysregulation drives chromosomal instability (CIN) hallmarking cancers, where overexpression correlates with aneuploidy, proliferation, poor prognosis, and chemoresistance in oral, gastric, and other carcinomas; silencing induces senescence, underscoring therapeutic potential via SAC modulation.

References
https://pubmed.ncbi.nlm.nih.gov/25754611/ https://pubmed.ncbi.nlm.nih.gov/22497940/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%